FindTrial
Sign In

Assessing the value of biomarker in blood for predicting the severity of chest injury patients admitted in ICU.

Evaluating the plasma biomarker level of Ang-2, RAGE and Clara cell protein (CC16) in chest trauma patients admitted in the ICU and its ability to predict the severity and the outcome. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/086629
Enrollment
120
Registered
2025-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S00-T88- Injury, poisoning and certain other consequences of external causes

Interventions

Control Intervention1: Nil: Nil Control Intervention2: Nil: Nil

Sponsors

Dean Research Section
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Primary Admission 2. Require Intensive care 3. Admitted in ICU for 48 Hours 4. Trauma Within 24 Hours

Exclusion criteria

Exclusion criteria: 1. Burns 2. Head Injury 3. Died within 24 hours after trauma 4. Age >65 years 5. Any malignancy

Design outcomes

Primary

MeasureTime frame
To compare plasma levels of Ang-2, RAGE and CC16 biomarker on day 1 of ICU admission of chest trauma patientsTimepoint: At 24 hours—

Secondary

MeasureTime frame
1. Severity of chest trauma patients relation to the biomarker Ang -2, RAGE & CC16 2. Outcome of chest trauma patients in relation to the biomarker Ang -2, RAGE & CC16 3. Correlation between CC16, Angiopoietin 2 & RAGE & Injury severity score & AIS. 4. Mortality 5. Length of ICU Stays 6. Number of days of Intubated 7. Tracheostomy doneTimepoint: 1. At 24hours 2. At 24 hours 3. At 24 hours 4. 30 days 5. At 30 days 6. At 30 days 7. At 30 days—

Countries

India

Contacts

Public ContactYudhyavir Singh

AIIMS, New Delhi

yudhyavir@gmail.com9811140057

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026